CerviLenzCervical length, vaginal progesterone, and preterm birth are expected to be hot topics at the SMFM 32nd Annual Meeting, February 6–11 in Dallas, Texas.
Obstetricians and midwives can measure cervical length during any prenatal visit with the CerviLenz® device to identify patients with a short cervix who would benefit from a Maternal-Fetal Medicine consultation. Cervilenz Inc. is exhibiting in Booth #412.
Cervilenz Inc. is also pleased to announce that the company joined The Pregnancy Foundation’s Corporate Council. The Pregnancy Foundation (formerly The SMFM Foundation) supports fundamental research in Maternal-Fetal Medicine and development of cutting edge clinical skills of Maternal-Fetal Medicine specialists. Through our Giving Back campaign, we are proud to help advance care for pregnant moms and their babies with donations to charitable organizations.
Cervilenz Inc. has been selected to present at OneMedForum SF 2012. Dean Koch, President and CEO of Cervilenz Inc., will be presenting the company’s background, progress and future plans on Tuesday, January 10th at 2:50 pm at the Sir Francis Drake Hotel in San Francisco, California. OneMedForum is a prestigious conference for emerging healthcare companies.
“We are proud to be presenting at OneMedForum and look forward to sharing our corporate story with others in the healthcare venture industry,” said Mr. Koch. “As we continue to introduce the CerviLenz device to the obstetrics community, the response is overwhelmingly positive. And, we’re now at an exciting turning point, ready for commercial launch into a global market.”
Two new studies demonstrating the clinical utility of the CerviLenz® device were presented today at the 10th World Congress of Maternal and Neonatal Health in Rome, Italy. The CerviLenz device is simple to use and disposable, allowing cervical length measurement in
any health care setting and providing an immediate quantitative result.
The Congress sponsors include the World Health Organization, the European Association of Perinatal Medicine, the World Association of Perinatal Medicine, and the March of Dimes. Cervical length during pregnancy is the best predictor of preterm birth risk. At the Congress, experts from around the world came together in a scientific session, “Prevention of Prematurity and Care of the Premature,” to address this global public health epidemic affecting 13 millions babies every year. The President of the Congress, Gian Carlo Di Renzo, MD, PhD, addressed risk factors and interventions for preterm delivery and introduced the CerviLenz device as a cost-effective innovation with potential to improve maternity care worldwide.
This year the March of Dimes put a global twist on their Prematurity Campaign for November declaring November 17th World Prematurity Day. 12.9 million babies are born too soon every year around the world, and 1 million of those babies die. The U.S. has the second highest rate of prematurity in the world.
As always, we salute the March of Dimes, its volunteers, and partners worldwide for all they do to help moms have healthy babies. In honor of their great work educate women, pregnant and not, Cervilenz Inc. is making a donation to the March of Dimes Pregnancy and Newborn Health Education Center.
Cervilenz Inc. recently received its CE Mark and ISO 13485 Certification for the CerviLenz® device. This innovative medical device is used to measure vaginal cervical length to help obstetricians identify and manage pregnant women at high risk for premature birth.
Cervilenz Inc. also added to its already robust patent portfolio for the device. The company now holds 12 issued patents, including 5 in the United States, 5 in Europe (France, Germany, Italy, UK, and Spain), 1 in Japan, and 1 in Turkey. Ten additional patent applications are pending.
Join our community! Get CerviLenz announcements and research updates, learn more about how obstetricians and midwives are using the CerviLenz device, and interact with us and your colleagues. Plus, get all the latest news on preterm birth risk assessment, cervical length measurement, high risk patient management, therapies such as progesterone, and more!
This Web Site is intended for Medical Professionals only.
This Web Site and its content are copyright 2012 Cervilenz Inc.
